Forma Therapeutics, Inc.
11
2
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
27.3%
3 terminated/withdrawn out of 11 trials
62.5%
-24.0% vs industry average
9%
1 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Role: lead
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Role: lead
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Role: lead
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Role: lead
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
Role: lead
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
Role: lead
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Role: lead
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
Role: lead
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Role: lead
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Role: lead
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Role: collaborator
All 11 trials loaded